-transparent.png){kind=logo}
BACKGROUND Carvedilol has been shown to improve morbidity and mortality in patients with congestive heart failure (CHF). There are limited data of carvedilol use in patients on inotrope therapy. We present our experience with carvedilol titration in New York Heart Association (NYHA) class IIIb/IV patients stabilized on milrinone therapy, as a nonrandomized study with a parallel control group of patients never on inotropes. These patients achieved volume control and stabilization of their symptoms during the course of milrinone therapy. RESULTS Seventeen patients in class IIIb/IV CHF (group 1) on intermittent intravenous milrinone therapy and 15 patients in class II/IIIa compensated CHF (group 2) on standard triple heart failure therapy were titrated on carvedilol. Success and adverse events during titration were compared between the 2 groups. Fifteen (88%) patients in group 1 and 14 (93%) patients in group 2 were successfully titrated on carvedilol over 8.1 +/- 1.8 weeks and 6.7 +/- 2.8 weeks, respectively. The target dose of carvedilol (25 or 50 mg twice daily) was achieved in 13 (87%) patients (group 1) and 14 (93%) patients (group 2). Seven (47%) patients in group 1 and 4 (28%) patients in group 2 had adverse events during carvedilol titration. Eight (53%) patients in group 1 were weaned off milrinone over a period of 8.4 weeks after carvedilol titration, whereas the rest of the patients had reduction in the frequency of infusion. Ten (63%) patients in group 1 improved by one or more functional classes. CONCLUSIONS Patients in NYHA class IIIb/IV who are treated with inotropic therapy can be titrated on carvedilol after reaching a stable state while on milrinone and standard oral drugs. Most of these patients can be successfully weaned off of milrinone or have decreased frequency of infusions and demonstrate improved functional status. Prospective randomized trials are required to evaluate these observations made in a limited number of patients in class IIIb and IV CHF because the combination of milrinone and beta-blockers has never been adequately evaluated.
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
January 2005,
The American journal of geriatric cardiology,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
July 2006,
International heart journal,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
October 1975,
Angiology,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
August 2013,
Journal of pharmaceutical sciences,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
August 2008,
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
May 2005,
European journal of pharmacology,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
February 2012,
Journal of cardiovascular pharmacology,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
January 2018,
Open heart,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
April 2002,
Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc,
A Kumar, and
G Choudhary, and
C Antonio, and
V Just, and
A Jain, and
L Heaney, and
M A Papp
December 2001,
European journal of heart failure,
